EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Saved in:
| Title: | EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). |
|---|---|
| Authors: | Hennessy MA; Cancer Research @UCC, College of Medicine & Health, University College Cork, Cork, Ireland., Gatsonis C; Brown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA., Jacene H; Dana-Farber/Brigham Cancer Center, Boston, MA, USA., Connolly RM; Cancer Research @UCC, College of Medicine & Health, University College Cork, Cork, Ireland.; Cancer Trials Cork, CUH/UCC Cancer Center, Cork University Hospital, Cork, Ireland., Burnette BL; Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, USA., Stringer-Reasor EM; University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, AL, USA., Romanoff J; Brown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA., Taurone A; Brown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA., O'Sullivan CC; Mayo Clinic, Rochester, MN, USA., Le-Petross HT; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stearns V; John Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD, USA., Fowler AM; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Tang SC; Louisiana State University Health Sciences Center, New Orleans, LA, USA., Sepulveda KA; Baylor College of Medicine, Houston, TX, USA., DeMichele AM; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA., Mankoff DA; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA., Wolff AC; John Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2025 Nov; Vol. 21 (26), pp. 3377-3384. Date of Electronic Publication: 2025 Oct 05. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
